Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Corcept Therapeutics (CORT)

Corcept Q3 revenue rises to $207.6 million; net income falls to $19.7 million

Mixed Impact 3 of 5 earnings Written later

Corcept Therapeutics reported third quarter 2025 revenue of $207.6 million, up from $182.5 million a year earlier, but net income fell to $19.7 million from $47.2 million as operating expenses rose to $197.4 million. The company also modified its 2025 revenue guidance to $800 million to $850 million and said it added a new specialty pharmacy on October 1 to meet demand for Korlym.

Key points

  • Q3 2025 revenue was $207.6 million, compared with $182.5 million in Q3 2024.
  • Q3 2025 net income was $19.7 million, compared with $47.2 million; diluted EPS was $0.16, compared with $0.41.
  • Operating expenses were $197.4 million, compared with $135.9 million, reflecting spending to prepare for launches of relacorilant.
  • 2025 revenue guidance was modified to $800 million to $850 million; the NDA for relacorilant in hypercortisolism has a PDUFA date of December 30, 2025.

The filing

CompanyCorcept Therapeutics (CORT)
Form8-K, current report
Filed with the SECNov 4, 2025, 4:08 PM ET
Accession number0001628280-25-048814

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.